American Society of Hematology

SHERPA: Blue

People

  1. Tan
    Tan
  2. Hultcrantz
    Hultcrantz
  3. Lesokhin
    Lesokhin
  4. Mailankody
    Mailankody
  5. Shah
    Shah
  6. Korde
    Korde
  7. Giralt
    Giralt
  8. Hassoun
    Hassoun
  9. Shah
    Shah
  10. Landau
    Landau

Groups

  1. Hematologic Malignancies, Division of (60)
  2. CTCR Scholars (53)
  3. Center for Hematologic Malignancies (53)
  4. Department of Medicine (53)
  5. Hematologic Malignancies Research (53)
  6. Myeloma (53)
  7. Sloan Kettering Institute Postdocs (53)
  8. Survivorship Research (53)
  9. Bone Marrow Transplant (51)
  10. Hematology-Oncology Fellows (50)
Search Within
  1. "Carlyn Rose Tan"
Formats
  1. Meeting Abstract (53)
  2. Journal Article (6)
  3. Research Letter (1)
Groups
  1. Hematologic Malignancies, Division of (60)
  2. CTCR Scholars (53)
  3. Center for Hematologic Malignancies (53)
  4. Department of Medicine (53)
  5. Hematologic Malignancies Research (53)
  6. Myeloma (53)

More Groups

People
  1. Carlyn Rose Tan (60)
  2. Alexander Lesokhin (53)
  3. Malin Hultcrantz (53)
  4. Sham Mailankody (53)
  5. Urvi Shah (53)
  6. Neha Korde (52)

More People

Years
  1. 2025 (2)
  2. 2024 (24)
  3. 2023 (15)
  4. 2022 (8)
  5. 2021 (5)
  6. 2020 (6)
Publications
  1. Blood (54)
  2. Blood Advances (6)

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term follow-up of real-world teclistamab therapy for relapsed/refractory multiple myeloma from the IMWG Immunotherapy Working Group Committee
    Meeting Abstract

    Tan, C. R.; Asoori, S.; Nemirovsky, D.; Derkach, A.; Brunaldi, L.; Popat, R.; Lau, C.; Kastritis, E.; Martínez-Lopez, J.; Bansal, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world characteristics and treatment patterns of transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) as front-line treatment: Results from a multicenter chart review study
    Meeting Abstract

    Tan, C. R.; Gordan, L.; Dileo, R.; Mewawalla, P.; Larson, S. M.; Davies, F. E.; Oveisi, D.; Gupta-Werner, N.; Medhekar, R.; Cortoos, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real world evidence of outcomes of patients treated with talquetamab in a heavily pretreated population with multiple myeloma with high exposure to prior BCMA therapies- A report from the IMWG Consortium
    Meeting Abstract

    Janakiram, M.; Tan, C. R.; Popat, R.; Martínez Lopez, J.; Kastritis, E.; Lau, C.; Chng, W. J.; Kapoor, P.; Mian, H.; Hal, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Evaluation of the safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment; Results from an IMWG Bone Subcommittee study
    Meeting Abstract

    Terpos, E.; Ntanasis-Stathopoulos, I.; Kyriakou, C.; Tan, C. R.; Abildgaard, N.; Delforge, M.; Fantl, D. B. E.; Seehaus, C. M.; Carneiro, E.; João, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save